PatientsVille.com Logo


Antineoplastic Medical Research Studies

Up-to-date List of Antineoplastic Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Antineoplastic Medical Research Studies

Rank Status Study
1 Recruiting Impact of a Coordinated Regional Organization to Secure Patient's Care Treated by Oral Antineoplastic Agents
Condition: Cancer
Outcome Measures: Number of early or unforeseen recourses to hospital for adverse event.;   all deaths and deaths from AE;   number of hospitalization for AE;   number of consultation for AE;   number of early or unforeseen recourses to hospital for grade 1 / 2 AE;   disease progression;   drug dose-intensity taken by the patient during his treatment;   number of recourses to the health care system;   number of AE per detection grade, AE maximal grade, AE all grade;   quality of life;   patient's satisfaction;   medical economic evaluation
2 Recruiting Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Condition: Neoplasms, Breast
Interventions: Drug: Lapatinib in combination with an anti-cancer agent;   Drug: Lapatinib;   Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Outcome Measures: Safety and tolerability;   Efficacy
3 Recruiting Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma
Condition: Neuroblastoma Recurrent
Interventions: Drug: Dasatinib;   Drug: Rapamycin;   Drug: Irinotecan;   Drug: Temozolomide
Outcome Measures: The primary endpoint is progression-free survival (PFS);   Overall survival (OS);   Response to the investigational treatment after 4 and 8 courses of I/T and 1-year-follow-up in the RIST treatment arm;   Duration until adequate response to this treatment regimen;   Assessment of quality of life (Lansky and Karnofsky Scores);   Toxicity of this combination of drugs in children, adolescents and young adults with rNB;   Safety and tolerability of the investigational treatment;   Assessment of the prognostic relevance of International Neuroblastoma Risk Group (INRG) classification system on the event free survival;   Prognostic relevance of defined factors on the event free survival in this patient population (i.e. response assessment of HVA, VMA, NSE)
4 Unknown  Genetic Polymorphisms Predict Chemotherapeutic Outcomes in Patients With Metastatic Breast Cancer
Conditions: Breast Neoplasm;   Drug Therapy;   Polymorphism,Single Nucleotide
Outcome Measures: Response to chemotherapy;   Time to disease progression;   Overall survival;   Toxicity
5 Recruiting Tablet-based Patient Reported Outcome
Condition: Antineoplastic Agents
Intervention: Device: Tablet-based questionnaire
Outcome Measures: Feasibility of Tablet-based questionnaire of PRO;   Answered questionnaires per patient
6 Recruiting Phase 1/2 Study of Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia
Interventions: Drug: Idarubicin;   Drug: Cytarabine;   Drug: Lenalidomide (Revlimid®)
Outcome Measures: Number of Participants With Adverse Events (AEs) - Phase I Therapy;   Complete Response (CR) Plus Complete Response with Incomplete Count Recovery (CRi) Rates;   Number of Participants With Adverse Events (AEs) During Maintenance Therapy;   Number of Participants With Cytogenetic Remission;   Number of Participants with Progression-Free Survival (PFS);   Number of Participants With Overall Survival (OS);   Number of Participants with Relapse-Free Survival
7 Recruiting Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
Conditions: Advanced Pancreatic Cancer;   Metastatic Pancreatic Cancer;   Pancreatic Adenocarcinoma
Intervention: Drug: PRI-724
Outcome Measures: The Maximum Tolerated Dose (MTD) of PRI-724 + Gemcitabine measured by the number of dose limiting toxicities (DLTs) that occur.;   Pharmacokinetic parameters of C max , T max , AUC (tau), and t ½.;   Pharmacodynamic mRNA expression of survivin;   Evaluation of Antineoplastic activity of PRI-724 + gemcitabine per RECIST 1.1 criteria;   MMP7 levels in blood as ng/ml;   Gene expressions in hair follicle epithelial cells
8 Recruiting A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents
Condition: Neoplasm
Interventions: Drug: PF-05212384;   Drug: Docetaxel;   Drug: Cisplatin;   Drug: Dacomitinib
Outcome Measures: Number of participants with Dose-limiting toxicities (DLT);   Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Gene sequence data;   QTc interval;   Objective tumor response;   Levels of PI3K pathway protein biomarkers
9 Recruiting IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Procedure: Molecular imaging
Outcome Measures: Clinical utility;   Correlation PET scans & progression-free survival (PFS);   Correlation of DNA and RNA analyses to imaging, molecular analyses and follow-up data;   Correlation miRNA analysis to molecular analyses, imaging & clincal follow-up data;   Correlation of peptide profiling to all other molecular, imaging and clinical follow-up data;   Correlation of standard pathology results to all molecular, imaging and clinical follow up data.;   Correlation of CTC analysis to all molecular, imaging and clinical follow-up data;   Correlation circulating tumor DNA analysis to all other molecular, imaging and clinical follow-up data;   Cost-effectiveness of molecular imaging;   QoL
10 Not yet recruiting EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells
Condition: Urothelial Carcinoma
Outcome Measure: The IHC staining score
11 Unknown  Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients
Condition: Nasopharyngeal Cancer
Outcome Measure:
12 Recruiting Multicenter Clinical Trial for Adult Ph-negative ALL. Continuous Treatment With Modification of Cytostatic Drugs Doses Depending on Myelosuppression Severity
Condition: Ph-negative Adult Acute Lymphoblastic Leukemia
Intervention: Drug: L-asparaginase
Outcome Measures: Proportion of adult ALL patients who tolerated the non-interrupted treatment;   Toxicity of prolonged L-asparaginase in adult patients
13 Recruiting Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Chronic Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts
Interventions: Other: antitumor drug screening assay;   Drug: chemotherapy;   Biological: biological therapy
Outcome Measures: Achievability of performing individualized drug screening and initiating therapy based on the results of the drug screen for poor risk patients with relapsed or refractory AML;   Change in the rate of complete response, defined by criteria of Cheson et al.
14 Recruiting Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Conditions: Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Lymphoma;   Neurotoxicity;   Radiation Toxicity
Interventions: Biological: rituximab;   Drug: cytarabine;   Drug: methotrexate;   Drug: procarbazine hydrochloride;   Drug: vincristine sulfate;   Radiation: whole-brain radiation therapy
Outcome Measures: Progression free survival (PFS) defined as the interval from randomization to progression or death, whichever occurs first;   Overall survival (OS) defined as the interval from randomization to death due to any cause;   Response rate (partial response or complete response);   Quality of life measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core/Brain Cancer Module (QLQ-C30/BCM20);   Neurocognitive function measured by the Hopkins Verbal Learning Test-Revised (HVLT-R), Trail Making Test Part A, Trail Making Test Part B, Controlled Oral Word Association Test (COWAT)
15 Recruiting Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury
Conditions: Neoplasms;   Liver Injury
Intervention: Drug: Magnesium Isoglycyrrhizinate Injection
Outcome Measure: The incidence of liver injury
16 Unknown  Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents
Conditions: Solid Tumors;   Hematological Malignancies;   Chemotherapy-induced Febrile Neutropenia
Outcome Measures: Safety of Nivestim® to reduce or prevent febrile neutropenia in patients treated with toxic chemotherapeutic agents for solid tumors or hematological malignancies.;   Efficacy and respect of Nivestim® treatment indications.
17 Recruiting Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer
Conditions: Chemotherapeutic Agent Toxicity;   Dermatologic Complications;   Palmar-plantar Erythrodysesthesia;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: pyridoxine hydrochloride;   Drug: capecitabine;   Procedure: complementary or alternative medicine procedure
Outcome Measures: First incidence of hand-foot syndrome (HFS) ≥ grade 2 according to NCI CTCAE vs 3.0;   Time to the onset of HFS ≥ grade 2;   Quality of life as measured by EuroQOL (EQ-5D) questionnaire
18 Unknown  Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
Conditions: Chemotherapeutic Agent Toxicity;   Colorectal Cancer;   Neurotoxicity
Interventions: Drug: FOLFOX regimen;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
Outcome Measure: Correlation of genetic profiles and peptide, protein, and neurotrophic factors with neurological toxicity
19 Unknown  First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer
Conditions: Chemotherapeutic Agent Toxicity;   Fatigue;   Lung Cancer;   Musculoskeletal Complications
Interventions: Drug: carboplatin;   Drug: vinorelbine tartrate;   Other: neuromuscular electrical stimulation;   Other: physiologic testing;   Procedure: fatigue assessment and management;   Procedure: quality-of-life assessment
Outcome Measures: Adherence to neuromuscular electrical stimulation (NMES) therapy;   Safety of NMES;   Quadriceps muscle strength;   Body composition;   Physical activity level;   Nutritional intake;   Fatigue;   Quality of life using the EORTC-C30 and LC-13 questionnaire;   Overall objective clinical response to chemotherapy
20 Unknown  Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors
Conditions: Chemotherapeutic Agent Toxicity;   Renal Toxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cisplatin;   Drug: ifosfamide;   Other: laboratory biomarker analysis
Outcome Measures: Evolution of different biomarkers;   Sensitivity, specificity, and predictive value (positive and negative) of different markers

These studies may lead to new treatments and are adding insight into Antineoplastic etiology and treatment.

A major focus of Antineoplastic research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Antineoplastic